References
- Crockett SD, Greer KB, Heidelbaugh JJ American gastroenterological association institute guideline on the medical management of opioid-induced constipation. Gastroenterology. 2019 Jan;156(1):218–226.
- De Giorgio R, Zucco FM, Chiarioni G Management of opioid-induced constipation and bowel dysfunction: expert opinion of an italian multidisciplinary panel. Adv Ther. 2021 Jul;38(7):3589–3621.
- Farmer AD, Drewes AM, Chiarioni G Pathophysiology and management of opioid-induced constipation: european expert consensus statement. UEG Journal. 2019 Feb;7(1):7–20.
- Vijayvargiya P, Camilleri M, Vijayvargiya P Systematic review with meta-analysis: efficacy and safety of treatments for opioid-induced constipation. Aliment Pharmacol Ther. 2020 Jul;52(1):37–53.
- Allen-Brady K, Tuteja AK. Chapter 33 - Opioid-induced bowel disorder and narcotic bowel syndrome. In: Rao SSC, Lee YY, Ghoshal UC, editors. Clinical and basic neurogastroenterology and motility. Academic Press; 2020. p. 463–475.
- Rekatsina M, Paladini A, Drewes AM Efficacy and safety of peripherally acting μ-opioid receptor antagonist (PAMORAs) for the management of patients with opioid-induced constipation: a systematic review. Cureus. 2021 Jul;13(7):e16201.
- Sarrió RG, Calsina-Berna A, García AG Delphi consensus on strategies in the management of opioid-induced constipation in cancer patients. BMC Palliat Care. 2021 Jan 2;20(1):1.
- Søndergaard J, Christensen HN, Ibsen R Healthcare resource use and costs of opioid-induced constipation among non-cancer and cancer patients on opioid therapy: a nationwide register-based cohort study in Denmark. Scand J Pain. 2017 Apr;15(1):83–90.
- Peacock WF, Slatkin N, Gagnon-Sanschagrin P Opioid-induced constipation: cost impact of approved medications in the emergency department. Adv Ther. 2022 May;39(5):2178–2191.
- Fine PG, Chen YW, Wittbrodt E Impact of opioid-induced constipation on healthcare resource utilization and costs for cancer pain patients receiving continuous opioid therapy. Support Care Cancer. 2019 Feb;27(2):687–696.
- Engle AL, Winans ARM. Rethinking docusate’s role in opioid-induced constipation: a critical analysis of the evidence. J Pain Palliat Care Pharmacother. 2021 Mar;35(1):63–72.
- Ouyang R, Li Z, Huang S Efficacy and safety of peripherally acting mu-opioid receptor antagonists for the treatment of opioid-induced constipation: a bayesian network meta-analysis. Pain medicine (Malden, Mass). 2020 Nov 1;21(11):3224–3232.
- Galligan JJ, Sternini C. Insights into the role of opioid receptors in the gi tract: experimental evidence and therapeutic relevance. Handb Exp Pharmacol. 2017;239:363–378.
- Poulsen JL, Brock C, Olesen AE Clinical potential of naloxegol in the management of opioid-induced bowel dysfunction. Clin Exp Gastroenterol. 2014;7:345–358.
- Poulsen JL, Nilsson M, Brock C The impact of opioid treatment on regional gastrointestinal transit. J Neurogastroenterol Motil. 2016 Apr 30;22(2):282–291.
- Mark EB, Nedergaard RB, Hansen TM Tapentadol results in less deterioration of gastrointestinal function and symptoms than standard opioid therapy in healthy male volunteers. Neurogastroenterology Motil off J Eur Gastrointestinal Motil Soc. 2021 Nov;33(11):e14131.
- Wirz S, Nadstawek J, Elsen C Laxative management in ambulatory cancer patients on opioid therapy: a prospective, open-label investigation of polyethylene glycol, sodium picosulphate and lactulose. Eur J Cancer Care (Engl). 2012 Jan;21(1):131–140.
- Hawley P, MacKenzie H, Gobbo M. PEG vs. sennosides for opioid-induced constipation in cancer care. Support Care Cancer. 2020 Apr;28(4):1775–1782.
- Emmanuel A, Johnson M, McSkimming P Laxatives Do Not Improve Symptoms of Opioid-Induced Constipation: results of a Patient Survey. Pain medicine (Malden, Mass). 2017 Oct 1;18(10):1932–1940.
- Lang-Illievich K, Bornemann-Cimenti H. Opioid-induced constipation: a narrative review of therapeutic options in clinical management. Korean J Pain. 2019 Apr 1;32(2):69–78.
- Maryland USFDANALOXONEHYDROCHLORIDE, United States: u.S. Food and Drug Administration 2022 [cited 2022 August 13]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215457s000lbl.pdf
- TGA. NARCAN naloxone hydrochloride Symonston, Australia Therapeutic Goods Administration; 2022 [cited 2022 August 13]. Available from: https://www.ebs.tga.gov.au/servlet/xmlmillr6?dbid=ebs/PublicHTML/pdfStore.nsf&docid=DA25D0E21B6BF597CA25871B004267AA&agid=(PrintDetailsPublic)&actionid=1
- EMA. Nyxoid Amsterdam Netherlands: European Medicines Agency; 2022 [cited 2022 August 13]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/nyxoid
- EMA. Oxynal Targin Amsterdam, Netherlands: European Medicines Agency; 2022 [cited 2022 August 14]. Available from: https://www.ema.europa.eu/en/medicines/human/referrals/oxynal-targin-associated-names
- EMA. Rizmoic Amsterdam Netherlands: European Medicines Agency; 2022 [cited 2022 August 14]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/rizmoic
- TGA. Symproic Symonston, Australia: Therapeutic Goods Administration; 2017 [cited 2022 August 14]. Available from: https://www.pmda.go.jp/files/000222647.pdf
- Dupoiron D, Stachowiak A, Loewenstein O A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone-naloxone (up to 160/80 mg daily) vs oxycodone PR. Eur J Pain. 2017 Oct;21(9):1528–1537.
- Huang L, Zhou JG, Zhang Y Opioid-Induced Constipation Relief From Fixed-Ratio Combination Prolonged-Release Oxycodone/Naloxone Compared With Oxycodone and Morphine for Chronic Nonmalignant Pain: a Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Pain Symptom Manage. 2017 Nov;54(5):737–748.e3.
- Mozaffari S, Nikfar S, Abdollahi M. Investigational opioid antagonists for treating opioid-induced bowel dysfunction. Expert Opin Investig Drugs. 2018 Mar;27(3):235–242.
- USFDA. TARGINIQ ER (oxycodone hydrochloride and naloxone hydrochloride extended-release tablets) Maryland United States: U.S. Food and Drug Administration 2016 [cited 2022 August 14]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/205777s004lbl.pdf
- USFDA. ENTEREG (alvimopan) Maryland, United States: u.S. Food and Drug Administration 2008 [cited 2022 August 14]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021775lbl.pdf
- Jansen JP, Lorch D, Langan J A randomized, placebo-controlled phase 3 trial (Study SB-767905/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain. J Pain. 2011 Feb;12(2):185–193.
- Mozaffari S, Nikfar S, Abdollahi M. Methylnaltrexone bromide for the treatment of opioid-induced constipation. Expert Opin Pharmacother. 2018 Jul;19(10):1127–1135.
- USFDA. RELISTOR (methylnaltrexone bromide) Maryland, United States: u.S. Food and Drug Administration; 2016 [cited 2022 August 13]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208271s000lbl.pdf
- TGA. RELISTOR methylnaltrexone bromide Symonston, Australia: therapeutic Goods Administration; 2022 [cited 2022 August 13]. Available from: https://www.ebs.tga.gov.au/servlet/xmlmillr6?dbid=ebs/PublicHTML/pdfStore.nsf&docid=144062&agid=(PrintDetailsPublic)&actionid=1
- EMA. Relistor Amsterdam Netherlands: European Medicines Agency; 2022 [cited 2022 August 13]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/relistor
- Szydziak K, Przekopinska B, Macioch T. PDG2 METHYLNALTREXONE FOR OPIOID-INDUCED CONSTIPATION IN PATIENTS RECEIVING PALLIATIVE CARE: a SYSTEMATIC REVIEW. Value Health. 2019;22:S597.
- Zhang YY, Zhou R, Gu WJ. Efficacy and safety of methylnaltrexone for the treatment of opioid-induced constipation: a meta-analysis of randomized controlled trials. Pain Ther. 2021 Jun;10(1):165–179.
- Patel PB, Brett SJ, O’Callaghan D Methylnaltrexone for the treatment of opioid-induced constipation and gastrointestinal stasis in intensive care patients. Results from the MOTION trial. Intensive Care Med. 2020 Apr;46(4):747–755.
- USFDA. MOVANTIK (naloxegol) Maryland, United States: u.S. Food and Drug Administration; 2014 [cited 2022 Aug 13]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204760s000lbl.pdf
- EMA. Moventig Amsterdam Netherlands: European Medicines Agency; 2022 [cited 2022 August 13]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/moventig
- TGA. MOVANTIK Symonston, Australia: Therapeutic Goods Administration; 2016 [cited 2022 August 13]. Available from: https://www.tga.gov.au/sites/default/files/auspar-naloxegol-oxalate-160601-pi.pdf
- Davies A, Cinieri S, Dupoiron D A Prospective, Real-World, Multinational Study of Naloxegol for Patients with Cancer Pain Diagnosed with Opioid-Induced Constipation-The NACASY Study. Cancers (Basel). 2022 Feb 23;14(5):1128.
- Cobo Dols M, Beato Zambrano C, Cabezón-Gutiérrez L One-year efficacy and safety of naloxegol on symptoms and quality of life related to opioid-induced constipation in patients with cancer: KYONAL study. BMJ Support Palliat Care. 2021 Mar 11;11(1):25–31.
- Zambrano CB, Dols MC, Gutiérrez LC 1868P Efficacy and safety of naloxegol in patients with cancer with opioid-induced constipation with laxative-inadequate response: a long-term, real-world study. Ann Oncol. 2020;31:S1066.
- Cobo Dols M, Beato Zambrano C, Cabezón Gutiérrez L Efficacy of naloxegol on symptoms and quality of life related to opioid-induced constipation in patients with cancer: a 3-month follow-up analysis. BMJ Support Palliat Care. 2021 Mar;11(1):25–31.
- Cobo Dols M, Beato Zambrano MDC, Cabezón Gutiérrez L 1821P - Analysis of the efficacy of naloxegol in a real-world 12 weeks of follow-up study, in patients with cancer and opioid-induced constipation with laxative-inadequate response. Ann Oncol. 2019 [2019 oct 01];30:v740.
- Lawson R, Ryan J, King F Cost Effectiveness of Naloxegol for Opioid-Induced Constipation in the UK. PharmacoEconomics. 2017 Feb;35(2):225–235.
- USFDA. SYMPROIC (naldemedine) Maryland, United States: u.S. Food and Drug Administration 2017 [cited 2022 Aug 14]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208854s000lbl.pdf
- Blair HA. Naldemedine: a Review in Opioid-Induced Constipation. Drugs. 2019 Jul;79(11):1241–1247.
- Beale R, Conway P, Cai B PGI3 Indirect Treatment Comparisons And Network Meta-Analyses Of Naldemedine For The Treatment Of Opioid-Induced Constipation. Value Health. 2019;22:S178.
- Hale M, Wild J, Reddy J Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials. Lancet Gastroenterol Hepatol. 2017 Aug;2(8):555–564.
- Camilleri M, Hale M, Morlion B Naldemedine Improves Patient-Reported Outcomes of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain in the COMPOSE Phase 3 Studies. J Pain Res. 2021;14:2179–2189.
- Song X, Wang D, Qu X A meta-analysis of naldemedine for the treatment of opioid-induced constipation. Expert Rev Clin Pharmacol. 2019 Feb;12(2):121–128.
- BouSaba J, Sannaa W, Camilleri M. Update on the role of naldemedine in opioid-induced constipation in patients with chronic noncancer pain. Therap Adv Gastroenterol. 2022;15:17562848221078638.
- Osaka I, Ishiki H, Yokota T Safety and efficacy of naldemedine in cancer patients with opioid-induced constipation: a pooled, subgroup analysis of two randomised controlled studies. ESMO open. 2019;4(4):e000527.
- USFDA. Linzess (Linaclotide) Maryland, United States: u.S. Food and Drug Administration 2017 [cited 2022 August 13]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202811s013lbl.pdf
- PMDA. List of Approved Products Tokyo, Japan Pharmaceuticals and Medical Devices Agency; 2022 [cited 2022 August 13]. Available from: https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html
- TGA. CONSTELLA linaclotide 290 microgram hard capsule bottle Symonston, Australia Therapeutic Goods Administration; 2019 [cited 2022 August 13]. Available from: https://www.ebs.tga.gov.au/servlet/xmlmillr6?dbid=ebs/PublicHTML/pdfStore.nsf&docid=84C1E315FD38B06CCA2587300042389F&agid=(PrintDetailsPublic)&actionid=1
- Mousavi T, Nikfar S, Abdollahi M. An update on efficacy and safety considerations for the latest drugs used to treat irritable bowel syndrome. Expert opinion on drug metabolism & toxicology. 2020;16(7):583–604.
- Brenner DM, Argoff CE, Fox SM Efficacy and safety of linaclotide for opioid-induced constipation in patients with chronic noncancer pain syndromes from a phase 2 randomized study. Pain. 2020 May;161(5):1027–1036.
- TGA. Australian Public Assessment Report for Prucalopride Symonston, Australia: Therapeutic Goods Administration; 2011 [cited 2022 August 13]. Available from: https://www.tga.gov.au/sites/default/files/auspar-resotrans.pdf
- USFDA. MOTEGRITY (prucalopride) Maryland, United States: u.S. Food and Drug Administration 2018 [cited 2022 Aug 13]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210166s000lbl.pdf
- USFDA. AMITIZA (lubiprostone) Maryland, United States: u.S. Food and Drug Administration 2018 [cited 2022 August 13]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021908s016lbl.pdf
- Japan P Amitiza Gets Label Update for Opioid-Induced Constipation: Pharma Japan; 2021 [cited 2022 August 13]. Available from: https://pj.jiho.jp/article/245632
- Webster LR, Brewer RP, Lichtlen P Efficacy of Lubiprostone for the Treatment of Opioid-Induced Constipation, Analyzed by Opioid Class. Pain Med. 2018 Jun 1;19(6):1195–1205.
- Sugimoto M, Murata M, Mizuno H. Differences in efficacy and safety of lubiprostone used for idiopathic vs opioid-induced constipation: meta-analysis of East Asian and Western populations. J Clin Biochem Nutr. 2020 May;66(3):184–192.
- Laugsand EA, Kaasa S, Klepstad P. Management of opioid-induced nausea and vomiting in cancer patients: systematic review and evidence-based recommendations. Palliat Med. 2011 Jul;25(5):442–453.
- Keeley PW. Nausea and vomiting in people with cancer and other chronic diseases. BMJ Clin Evid. 2009 Jan 13;2009:2406.
- Okamoto Y, Tsuneto S, Matsuda Y A retrospective chart review of the antiemetic effectiveness of risperidone in refractory opioid-induced nausea and vomiting in advanced cancer patients. J Pain Symptom Manage. 2007 Aug;34(2):217–222.
- Osman AAM, Elhassan MMA, AbdElrahim BHA Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting: a Comparative Study From Sudan. J Glob Oncol. 2018 Sep;4:1–9.
- Hardy J, Daly S, McQuade B A double-blind, randomised, parallel group, multinational, multicentre study comparing a single dose of ondansetron 24 mg p.o. with placebo and metoclopramide 10 mg t.d.s. p.o. in the treatment of opioid-induced nausea and emesis in cancer patients. Support Care Cancer. 2002 Apr;10(3):231–236.
- Sussman G, Shurman J, Creed MR Intravenous ondansetron for the control of opioid-induced nausea and vomiting. International S3AA3013 Study Group. Clin Ther. 1999 Jul;21(7):1216–1227.
- Chung F, Lane R, Spraggs C Ondansetron is more effective than metoclopramide for the treatment of opioid-induced emesis in post-surgical adult patients. Ondansetron OIE Post-Surgical Study Group. Eur J Anaesthesiol. 1999 Oct; 1610:669–677.
- Rossi M, Casale G, Badiali D Opioid-induced bowel dysfunction: suggestions from a multidisciplinary expert Board. Support Care Cancer. 2019 Nov;27(11):4083–4090.
- Mesía R, Virizuela Echaburu JA, Gómez J Opioid-Induced Constipation in Oncological Patients: new Strategies of Management. Curr Treat Options Oncol. 2019 Dec 19;20(12):91.
- Saha S, Nathani P, Gupta A. Preventing Opioid-Induced Constipation: a Teachable Moment. JAMA Intern Med. 2020 Oct 1;180(10):1371–1372.
- Ginex PK, Hanson BJ, LeFebvre KB Management of Opioid-Induced and Non-Opioid-Related Constipation in Patients With Cancer: systematic Review and Meta-Analysis. Oncol Nurs Forum. 2020 Nov 1;47(6):E211–e224.
- Rogers B, Ginex PK, Anbari A ONS Guidelines™ for Opioid-Induced and Non-Opioid-Related Cancer Constipation. Oncol Nurs Forum. 2020 Nov 1;47(6):671–691.
- Ozaki A, Kessoku T, Tanaka K Effectiveness of Naldemedine Compared with Magnesium Oxide in Preventing Opioid-Induced Constipation: a Randomized Controlled Trial. Cancers (Basel). 2022 Apr 24;14(9):2112.
- AL N. Opioid-Induced Constipation in Advanced Cancer Patients. Cureus. 2021 Apr 9;13(4):e14386.
- Garcia JM, Shamliyan TA. Management of opioid-induced constipation in patients with malignancy. Am J Med. 2018;131(9):1041–1051. e3.
- Saleem R, Syed T, Nusrat S Effectiveness of Various Treatment Agents for Opioid-Induced Constipation: a Meta-Analysis: 428. Am J Gastroenterol. 2017;112:S229.
- Nee J, Zakari M, Sugarman MA Efficacy of Treatments for Opioid-Induced Constipation: systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2018 Oct;16(10):1569–1584.e2.
- Nishie K, Yamamoto S, Yamaga T Peripherally acting μ-opioid antagonist for the treatment of opioid-induced constipation: systematic review and meta-analysis. J Gastroenterol Hepatol. 2019 May;34(5):818–829.
- Argoff CE. Opioid-induced Constipation: a Review of Health-related Quality of Life, Patient Burden, Practical Clinical Considerations, and the Impact of Peripherally Acting μ-Opioid Receptor Antagonists. Clin J Pain. 2020 Sep;36(9):716–722.
- Novak C, Hogg A, Sue K Peripherally acting μ-opioid receptor antagonists for treatment of opioid-induced constipation in children. Paediatr Child Health. 2021 Apr-May;26(2):e105–e109.
- Rosenberg JB. Recognizing and Treating Opioid-Induced Constipation in Chronically Ill Children. Pediatr Nurs. 2019;45(1):p7–46.
- Drossman D, Szigethy E. The narcotic bowel syndrome: a recent update. Am. J. Gastroenterol. Suppl. 2014 Sep 10;2(1):22–30.
- Farmer AD, Gallagher J, Bruckner-Holt C Narcotic bowel syndrome. Lancet Gastroenterol Hepatol. 2017;2(5):361–368.
- Cherny N, Ripamonti C, Pereira J Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol. 2001 May 1;19(9):2542–2554.
- McDonald P, Graham P, Clayton M Regular subcutaneous bolus morphine via an indwelling cannula for pain from advanced cancer. Palliat Med. 1991 [1991 oct 01];5(4):323–329.
- Sande TA, Laird BJA, Fallon MT. The Management of Opioid-Induced Nausea and Vomiting in Patients with Cancer: a Systematic Review. J Palliat Med. 2019 Jan;22(1):90–97.